Nanobiotix Cash Flow Conversion Efficiency
Nanobiotix cash flow conversion efficiency. Based on the latest financial reports, Nanobiotix (NBTX) has a cash flow conversion efficiency ratio of 0.190x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.01 Million) by net assets ($-84.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nanobiotix (2011–2025)
Cash flow conversion efficiency of Nanobiotix from 2011 to 2025. This chart illustrates how Nanobiotix's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Nanobiotix for real-time trading data and today's change.
Nanobiotix Cash Flow Conversion Ratio Explained
Nanobiotix cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nanobiotix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanobiotix ranked by their cash flow conversion efficiency. Also see NBTX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ShenZhen QiangRui Precision Technology Co. Ltd.
SHE:301128
|
0.008x |
|
Opera Limited
F:2V8
|
0.043x |
|
MillerKnoll Inc
NASDAQ:MLKN
|
0.046x |
|
Kinpo Electronics Inc
TW:2312
|
-0.025x |
|
Ningbo Donly Co Ltd
SHE:002164
|
0.025x |
|
BlackRock Capital Allocation Trust
NYSE:BCAT
|
N/A |
|
Quantum Computing Inc
NASDAQ:QUBT
|
-0.007x |
|
Healthcare Services Group Inc
NASDAQ:HCSG
|
0.048x |
Annual Cash Flow Conversion Efficiency for Nanobiotix (2011–2025)
The table below shows the annual cash flow conversion efficiency of Nanobiotix from 2011 to 2025. Review Nanobiotix (NBTX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-84.48 Million | $-33.42 Million | 0.396x | +32.95% |
| 2024-12-31 | $-65.70 Million | $-19.55 Million | 0.298x | -95.60% |
| 2023-12-31 | $-1.84 Million | $-12.48 Million | 6.766x | +393.17% |
| 2022-12-31 | $-27.05 Million | $-37.10 Million | 1.372x | +223.04% |
| 2021-12-31 | $26.79 Million | $-29.87 Million | -1.115x | -185.33% |
| 2020-12-31 | $70.47 Million | $-27.54 Million | -0.391x | -101.81% |
| 2019-12-31 | $-1.91 Million | $-41.17 Million | 21.566x | +1282.07% |
| 2018-12-31 | $14.24 Million | $-25.98 Million | -1.824x | -282.51% |
| 2017-12-31 | $43.92 Million | $-20.95 Million | -0.477x | +54.61% |
| 2016-12-31 | $17.40 Million | $-18.28 Million | -1.051x | +2.47% |
| 2015-12-31 | $15.61 Million | $-16.82 Million | -1.077x | -281.37% |
| 2014-12-31 | $30.32 Million | $-8.56 Million | -0.283x | +86.84% |
| 2013-12-31 | $3.18 Million | $-6.83 Million | -2.147x | -511.35% |
| 2012-12-31 | $10.70 Million | $-3.76 Million | -0.351x | +93.33% |
| 2011-12-31 | $925.53K | $-4.87 Million | -5.265x | -- |
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more